This study aims to describe the severe symptom trajectory in MM population who utilized remote symptom monitoring with ePRO.
CareviveMay 18, 2023
In this study, we used electronic patient-reported outcomes (ePRO) through a remote symptom monitoring program in MM patients experiencing variable levels of pain.
CareviveMay 18, 2023
This study demonstrates the feasibility of gathering PROs with real-world data among a cohort of patients with AML using a remote symptom monitoring platform, across baseline prognostic and therapeutic factors.
CareviveDecember 12, 2022
The aim of this study was to determine feasibility of patients using a touchscreen computer to record goals, preferences and top concerns to share with the physician at a treatment decision visit.
CareviveDecember 12, 2022
Previous studies have shown that frailty scores aid in better patient assessment and in advising treatment strategies for Acute Myeloid Leukemia (AML) (Jamy, et al., 2021), and Multiple Myeloma (Nathwani, et al., 2017, 2019). This study aims to evaluate the impact of frailty status on treatment choices among breast cancer patients.
CareviveDecember 9, 2022
Women undergoing treatment for breast cancer experience both disease- and treatment-related symptoms. Remote symptom management (RSM) programs allow real-time symptom documentation, earlier intervention, and opportunities to improve quality of life and decrease symptom burden. Prior studies have focused on the supportive care needs of women with advanced breast cancer.
CareviveDecember 9, 2022
Continuous temperature monitoring (CTM) identifies fever earlier than the standard of care1 and symptom detection and documentation is improved using electronic Patient Reported Outcomes (ePRO).
CareviveNovember 14, 2022
Overall results demonstrate the feasibility of gathering patient perspectives such as QoL preference, perceptions of durability, and treatment concerns in routine practice.
CareviveMay 19, 2022
The objective of this study is to characterize initial treatment burden in oncology patients, by assessing health resource utilization (HRU) and dose modification, with and without active symptom monitoring.
CareviveMay 19, 2022
